{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:12Z","timestamp":1747207332846,"version":"3.40.5"},"reference-count":56,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"name":"Shanghai Institute for Food and Drug Control","award":["2014-SKT- 13"],"award-info":[{"award-number":["2014-SKT- 13"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Neurofibromatosis, also known as Von Recklinghausen disease, is a\nsystemic and progressive genetic disease that primarily affects the skin, eyes, nervous system, and\nbones. The disease can occur in a variety of ways and can vary in individuals. Metabolomic-based\nresearch using blood samples has enabled new diagnostic methods to be used in the diagnosis of\nvarious diseases, especially cancer. Among the metabolites, profiling of plasma free amino acids\n(PFAA) is a promising approach because PFAAs bind all organ systems and play an important role\nin the metabolism.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to determine the characteristics of PFAA profiles in neurofibromatosis\npatients and the possibility of using them for early detection and treatment of the disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Patients with a diagnosis of Neurofibromatosis Type I confirmed by genetic\nanalysis and healthy individuals of the same age group without any disease were included in\nthe study. We analysed the nineteen plasma free amino acids (phenylalanine, proline,\nthreonine, arginine, asparagine, cystine, valine, glutamate, tyrosine, serine, glutamine,\nglycine, tryptophane, leucine, lysine, methionine, isoleucine, aspartate and alanine) from\nneurofibromatosis Type I patients and control group by liquid chromatography tandem mass\nspectrometry (LC-MS\/MS) in Metabolism Laboratory of Harran University Research and\nApplication Hospital. The results of the plasma free amino acid levels were divided into 3\ngroups as essential, semi-essential, and non-essential. The differences in amino acid levels\nbetween groups were determined.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The levels of eight amino acids (methionine, arginine, cystine, glutamine, proline,\nasparagine, serine, aspartate) were significantly altered in patients with neurofibromatosis type 1.\nIn essential amino acids, methionine levels were significantly higher in the patient group than\ncontrol group. While the levels of arginine and glutamine in semi-essential amino acids were\nstatistically significantly higher in the patient group, a significant decrease was observed in cystine\nand proline levels compared to the control group's amino acid levels. In the non-essential amino\nacids group, asparagine, serine and aspartate amino acid levels were significantly higher in the\npatient group compared to the control group.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> The current research predicates that eight amino acids, namely methionine, arginine,\ncystine, glutamine, proline, asparagine, serine, aspartate can be considered to be valuable\nbiomarkers for neurofibromatosis type I. This present study is the first to build models for\nneurofibromatosis Type I screening using plasma free amino acids and the amino acid profile will\nbe able to guide the prediction of the complications that may occur during the course of the\ndisease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207323666201204143206","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T07:24:56Z","timestamp":1607153096000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Pilot Study for Investigation of Plasma Amino Acid Profile in Neurofibromatosis Type 1 Patients"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-6025","authenticated-orcid":true,"given":"Ozlem","family":"Oz","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Harran University, Sanl\u0131urfa,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-4757","authenticated-orcid":true,"given":"Ismail","family":"Koyuncu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Biochemistry, Harran University, \u015eanl\u0131urfa,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7200-1537","authenticated-orcid":true,"given":"Ataman","family":"Gonel","sequence":"additional","affiliation":[{"name":"Department of Medicinal Biochemistry, Harran University, \u015eanl\u0131urfa,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","volume":"104","author":"Helfferich J.","year":"2016","unstructured":"Helfferich J.; Nijmeijer R.; Brouwer O.F.; Boon M.; Fock A.; Hoving E.W.; Meijer L.; den Dunnen W.F.; de Bont E.S.; Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol 2016,104,30-41","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"Conference N.C.D.","year":"1988","unstructured":"Conference N.C.D.; National institutes of health consensus development conference. Neurofibromatosis. Conference statement. Arch Neurol 1988,45(5),575-578","journal-title":"Arch Neurol"},{"year":"1991","author":"Marchuk D.A.","key":"ref=3","unstructured":"Marchuk D.A.; Saulino A.M.; Tavakkol R.; Swaroop M.; Wallace M.R.; Andersen L.B.; Mitchell A.L.; Gutmann D.H.; Boguski M.; Collins F.S.; cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. 1991"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/088307380201700804","volume":"17","author":"Viskochil D.","year":"2002","unstructured":"Viskochil D.; Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 2002,17(8),562-570","journal-title":"J Child Neurol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(90)90149-9","volume":"63","author":"Xu G.","year":"1990","unstructured":"Xu G.; Lin B.; Tanaka K.; Dunn D.; Wood D.; Gesteland R.; White R.; Weiss R.; Tamanoi F.J.C.; The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990,63(4),835-841","journal-title":"Cell"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/MCB.13.1.487","volume":"13","author":"Andersen L.B.","year":"1993","unstructured":"Andersen L.B.; Ballester R.; Marchuk D.A.; Chang E.; Gutmann D.H.; Saulino A.M.; Camonis J.; Wigler M.; Collins F.S.; A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol 1993,13(1),487-495","journal-title":"Mol Cell Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"15996","DOI":"10.1073\/pnas.1019012108","volume":"108","author":"Banerjee S.","year":"2011","unstructured":"Banerjee S.; Crouse N.R.; Emnett R.J.; Gianino S.M.; Gutmann D.H.; Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC\/Rheb-independent manner. Proc Natl Acad Sci USA 2011,108(38),15996-16001","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/ng2004","volume":"39","author":"Tong J.J.","year":"2007","unstructured":"Tong J.J.; Schriner S.E.; McCleary D.; Day B.J.; Wallace D.C.J.N.g.;  Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster 2007,39(4),476-485","journal-title":"Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.5604\/17322693.1185213","volume":"69","author":"Abramowicz A.","year":"2015","unstructured":"Abramowicz A.; Gos M.; Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis. Postepy Hig Med Dosw 2015,69,1331-1348","journal-title":"Postepy Hig Med Dosw"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/ejhg.2014.243","volume":"23","author":"Pinna V.","year":"2015","unstructured":"Pinna V.; Lanari V.; Daniele P.; Consoli F.; Agolini E.; Margiotti K.; Bottillo I.; Torrente I.; Bruselles A.; Fusilli C.; Ficcadenti A.; Bargiacchi S.; Trevisson E.; Forzan M.; Giustini S.; Leoni C.; Zampino G.; Digilio M.C.; Dallapiccola B.; Clementi M.; Tartaglia M.; De Luca A.p.; Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet 2015,23(8),1068-1071","journal-title":"Eur J Hum Genet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/ejhg.2015.93","volume":"23","author":"Santoro C.","year":"2015","unstructured":"Santoro C.; Maietta A.; Giugliano T.; Melis D.; Perrotta S.; Nigro V.; Piluso G.; Arg(1809) substitution in neurofibromin: further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur J Hum Genet 2015,23(11),1460-1461","journal-title":"Eur J Hum Genet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1034\/j.1399-0004.2000.580501.x","volume":"58","author":"Hamilton S.","year":"2000","unstructured":"Hamilton S.; Friedman J.J.C.g.;  Insights into the pathogenesis of neurofibromatosis 1 vasculopathy 2000,58(5),341-344","journal-title":"Insights into the pathogenesis of neurofibromatosis 1 vasculopathy"},{"key":"ref=13","first-page":"508","volume":"10","author":"Brems H.","year":"2009","unstructured":"Brems H.; Beert E.; de Ravel T.; Legius E.J.T.l.o.;  Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1 2009,10(5),508-515","journal-title":"Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1"},{"key":"ref=14","first-page":"353","volume":"25","author":"Longo J.F.","year":"2018","unstructured":"Longo J.F.; Weber S.M.; Turner-Ivey B.P.; Carroll S.L.; Recent advances in the diagnosis and pathogenesis of neurofibromatosis type 1 (NF1)-associated peripheral nervous system neoplasms. 2018,25(5),353-368"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fgene.2019.00762","volume":"10","author":"Setrajcic Dragos V.","year":"2019","unstructured":"Setrajcic Dragos V.; Blatnik A.; Klancar G.; Stegel V.; Krajc M.; Blatnik O.; Novakovic S.J.F.i.G.;  Two novel NF1 pathogenic variants causing the creation of a new splice site in patients with neurofibromatosis type I 2019,10,762","journal-title":"Two novel NF1 pathogenic variants causing the creation of a new splice site in patients with neurofibromatosis type I"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/genes10110847","volume":"10","author":"Yao R.","year":"2019","unstructured":"Yao R.; Yu T.; Xu Y.; Yu L.; Wang J.; Wang X.; Wang J.; Shen Y.J.G.; Clinical presentation and novel pathogenic variants among 68 chinese neurofibromatosis 1 children. Genes (Basel) 2019,10(11),847","journal-title":"Genes (Basel)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/erc.12.121","volume":"11","author":"Kim O.Y.","year":"2013","unstructured":"Kim O.Y.; Lee J.H.; Sweeney G.J.E.r.o.c.t.; Metabolomic profiling as a useful tool for diagnosis and treatment of chronic disease: focus on obesity, diabetes and cardiovascular diseases. Expert Rev Cardiovasc Ther 2013,11(1),61-68","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41584-018-0136-z","volume":"15","author":"McGrath C.M.","year":"2019","unstructured":"McGrath C.M.; Young S.P.J.N.R.R.; Can metabolomic profiling predict response to therapy? Nature Reviews Rheumatol 2019,15(3),129-130","journal-title":"Nature Reviews Rheumatol"},{"key":"ref=19","first-page":"31","volume":"1","author":"&#xD6;zt&#xFC;rk A.","year":"2015","unstructured":"&#xD6;zt&#xFC;rk A.; The clinical aproach to metabolomics and proteomics concepts. Turkiye Klinikleri J Vet Sci Intern Med-Special Topics 2015,1(1),31-39","journal-title":"Turkiye Klinikleri J Vet Sci Intern Med-Special Topics"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024143","volume":"6","author":"Miyagi Y.","year":"2011","unstructured":"Miyagi Y.; Higashiyama M.; Gochi A.; Akaike M.; Ishikawa T.; Miura T.; Saruki N.; Bando E.; Kimura H.; Imamura F.; Moriyama M.; Ikeda I.; Chiba A.; Oshita F.; Imaizumi A.; Yamamoto H.; Miyano H.; Horimoto K.; Tochikubo O.; Mitsushima T.; Yamakado M.; Okamoto N.; Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011,6(9)","journal-title":"PLoS One"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41431-018-0296-y","volume":"27","author":"Imaizumi A.","year":"2019","unstructured":"Imaizumi A.; Adachi Y.; Kawaguchi T.; Higasa K.; Tabara Y.; Sonomura K.; Sato T.-a.; Takahashi M.; Mizukoshi T.; Yoshida H.-o.J.E.J.H.G.; Genetic basis for plasma amino acid concentrations based on absolute quantification: A genome-wide association study in the Japanese population. Eur J Human Genet 2019,27(4),621-630","journal-title":"Eur J Human Genet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ajhb.22787","volume":"28","author":"Nakamura H.","year":"2016","unstructured":"Nakamura H.; Nishikata N.; Kawai N.; Imaizumi A.; Miyano H.; Mori M.; Yamamoto H.; Noguchi, Plasma amino acid profiles in healthy East Asian subpopulations living in Japan. American J Human Biol 2016,28(2),236-239","journal-title":"American J Human Biol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12199-017-0642-7","volume":"22","author":"Yamaguchi N.","year":"2017","unstructured":"Yamaguchi N.; Mahbub M.; Takahashi H.; Hase R.; Ishimaru Y.; Sunagawa H.; Amano H.; Kobayashi-Miura M.; Kanda H.; Fujita, Plasma free amino acid profiles evaluate risk of metabolic syndrome, diabetes, dyslipidemia, and hypertension in a large Asian population. Environ Health Preven Med 2017,22(1),35","journal-title":"Environ Health Preven Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"11918","DOI":"10.1038\/srep11918","volume":"5","author":"Yamakado M.","year":"2015","unstructured":"Yamakado M.; Nagao K.; Imaizumi A.; Tani M.; Toda A.; Tanaka T.; Jinzu H.; Miyano H.; Yamamoto H.; Daimon T.J.S.r.;  Plasma free amino acid profiles predict four-year risk of developing diabetes, metabolic syndrome, dyslipidemia, and hypertension in Japanese population 2015,5,11918","journal-title":"Plasma free amino acid profiles predict four-year risk of developing diabetes, metabolic syndrome, dyslipidemia, and hypertension in Japanese population"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1042\/bj2980415","volume":"298","author":"Miller J.W.","year":"1994","unstructured":"Miller J.W.; Nadeau M.R.; Smith J.; Smith D.; Selhub J.; Folate-deficiency-induced homocysteinaemia in rats: disruption of S-adenosylmethionine\u2019s co-ordinate regulation of homocysteine metabolism. Biochem J 1994,298(Pt 2),415-419","journal-title":"Biochem J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1357-2725(99)00138-7","volume":"32","author":"Finkelstein J.D.","year":"2000","unstructured":"Finkelstein J.D.; Martin J.J.; Homocysteine. Int J Biochem Cell Biol 2000,32(4),385-389","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCGENETICS.109.852814","volume":"3","author":"Shah S.H.","year":"2010","unstructured":"Shah S.H.; Bain J.R.; Muehlbauer M.J.; Stevens R.D.; Crosslin D.R.; Haynes C.; Dungan J.; Newby L.K.; Hauser E.R.; Ginsburg G.S.; Newgard C.B.; Kraus W.E.; Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 2010,3(2),207-214","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ahj.2014.01.019","volume":"168","author":"Vaarhorst A.A.","year":"2014","unstructured":"Vaarhorst A.A.; Verhoeven A.; Weller C.M.; B&#xF6;hringer S.; G&#xF6;raler S.; Meissner A.; Deelder A.M.; Henneman P.; Gorgels A.P.; van den Brandt P.A.; A metabolomic profile is associated with the risk of incident coronary heart disease. Am Heart J 2014,168(1),45-52","journal-title":"Am Heart J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11306-011-0357-5","volume":"8","author":"Leichtle A.B.","year":"2012","unstructured":"Leichtle A.B.; Nuoffer J-M.; Ceglarek U.; Kase J.; Conrad T.; Witzigmann H.; Thiery J.; Fiedler G.M.; Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012,8(4),643-653","journal-title":"Metabolomics"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1524-475X.2003.11605.x","volume":"11","author":"Witte M.B.","year":"2003","unstructured":"Witte M.B.; Barbul A.; Arginine physiology and its implication for wound healing. Wound Repair Regen 2003,11(6),419-423","journal-title":"Wound Repair Regen"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00726-004-0078-4","volume":"26","author":"Satriano J.","year":"2004","unstructured":"Satriano J.; Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: Review article. Amino Acids 2004,26(4),321-329","journal-title":"Amino Acids"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0148607185009004428","volume":"9","author":"Tachibana K.","year":"1985","unstructured":"Tachibana K.; Mukai K.; Hiraoka I.; Moriguchi S.; Takama S.; Kishino Y.; Evaluation of the effect of arginine-enriched amino acid solution on tumor growth. JPEN J Parenter Enteral Nutr 1985,9(4),428-434","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0165-2478(90)90083-3","volume":"25","author":"Green S.J.","year":"1990","unstructured":"Green S.J.; Mellouk S.; Hoffman S.L.; Meltzer M.S.; Nacy C.A.; Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett 1990,25(1-3),15-19","journal-title":"Immunol Lett"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s726-002-8200-9","volume":"22","author":"M&#xFC;hling J.","year":"2002","unstructured":"M&#xFC;hling J.; Fuchs M.; Fleck C.; Sablotzki A.; Kr&#xFC;ll M.; Dehne M.G.; Gonter J.; Weiss S.; Engel J.; Hempelmann G.; Effects of arginine, L-alanyl-L-glutamine or taurine on neutrophil (PMN) free amino acid profiles and immune functions in vitro. Amino Acids 2002,22(1),39-53","journal-title":"Amino Acids"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/ajcn\/81.5.1142","volume":"81","author":"Vissers Y.L.","year":"2005","unstructured":"Vissers Y.L.; Dejong C.H.; Luiking Y.C.; Fearon K.C.; von Meyenfeldt M.F.; Deutz N.E.; Plasma arginine concentrations are reduced in cancer patients: Evidence for arginine deficiency? Am J Clin Nutr 2005,81(5),1142-1146","journal-title":"Am J Clin Nutr"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/1097-0142(19920501)69:9<2343::AIDCNCR2820690924>3.0.CO;2-S","volume":"69","author":"Kubota A.","year":"1992","unstructured":"Kubota A.; Meguid M.M.; Hitch D.C.; Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 1992,69(9),2343-2348","journal-title":"Cancer"},{"key":"ref=37","author":"Scriver C.R.","year":"2001","unstructured":"Scriver C.R.;  The metabolic  2001","journal-title":"The metabolic"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S0891-5849(99)00176-8","volume":"27","author":"Griffith O.W.","year":"1999","unstructured":"Griffith O.W.; Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999,27(9-10),922-935","journal-title":"Free Radic Biol Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"49841","DOI":"10.1074\/jbc.M205615200","volume":"277","author":"Pittman M.S.","year":"2002","unstructured":"Pittman M.S.; Corker H.; Wu G.; Binet M.B.; Moir A.J.; Poole R.K.; Cysteine is exported from the Escherichia coli cytoplasm by CydDC, an ATP-binding cassette-type transporter required for cytochrome assembly. J Biol Chem 2002,277(51),49841-49849","journal-title":"J Biol Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0197-0186(00)00035-8","volume":"37","author":"Bender A.S.","year":"2000","unstructured":"Bender A.S.; Reichelt W.; Norenberg M.D.; Characterization of cystine uptake in cultured astrocytes. Neurochem Int 2000,37(2-3),269-276","journal-title":"Neurochem Int"},{"key":"ref=41","first-page":"1188","volume":"12","author":"Zhang S.M.","year":"2003","unstructured":"Zhang S.M.; Willett W.C.; Selhub J.; Manson J.E.; Colditz G.A.; Hankinson S.E.; A prospective study of plasma total cysteine and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2003,12(11 Pt 1),1188-1193","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1096\/fasebj.11.1.9034170","volume":"11","author":"Hack V.","year":"1997","unstructured":"Hack V.; Schmid D.; Breitkreutz R.; Stahl-Henning C.; Drings P.; Kinscherf R.; Taut F.; Holm E.; Dr&#xF6;ge W.; Cystine levels, cystine flux, and protein catabolism in cancer cachexia, HIV\/SIV infection, and senescence. FASEB J 1997,11(1),84-92","journal-title":"FASEB J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/ijms18051051","volume":"18","author":"Kim M-H.","year":"2017","unstructured":"Kim M-H.; Kim H.; The roles of glutamine in the intestine and its implication in intestinal diseases. Int J Mol Sci 2017,18(5),1051","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1753-4887.1990.tb02967.x","volume":"48","author":"Lacey J.M.","year":"1990","unstructured":"Lacey J.M.; Wilmore D.W.; Is glutamine a conditionally essential amino acid? Nutr Rev 1990,48(8),297-309","journal-title":"Nutr Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0039-6060(99)70264-3","volume":"125","author":"Blikslager A.T.","year":"1999","unstructured":"Blikslager A.T.; Rhoads J.M.; Bristol D.G.; Roberts M.C.; Argenzio R.A.; Glutamine and transforming growth factor-&#x3B1; stimulate extracellular regulated kinases and enhance recovery of villous surface area in porcine ischemic-injured intestine. Surgery 1999,125(2),186-194","journal-title":"Surgery"},{"key":"ref=46","first-page":"G866","volume":"271","author":"Ziegler T.R.","year":"1996","unstructured":"Ziegler T.R.; Mantell M.P.; Chow J.C.; Rombeau J.L.; Smith R.J.; Gut adaptation and the insulin-like growth factor system: regulation by glutamine and IGF-I administration. Am J Physiol 1996,271(5 Pt 1),G866-G875","journal-title":"Am J Physiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"22830","DOI":"10.3390\/ijms160922830","volume":"16","author":"Chen L.","year":"2015","unstructured":"Chen L.; Cui H.; Targeting glutamine induces apoptosis: a cancer therapy approach. Int J Mol Sci 2015,16(9),22830-22855","journal-title":"Int J Mol Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S0891-5849(02)00826-2","volume":"32","author":"Dizdaroglu M.","year":"2002","unstructured":"Dizdaroglu M.; Jaruga P.; Birincioglu M.; Rodriguez H.; Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 2002,32(11),1102-1115","journal-title":"Free Radic Biol Med"},{"key":"ref=49","first-page":"1159","volume":"31","author":"Rudman D.","year":"1971","unstructured":"Rudman D.; Vogler W.R.; Howard C.H.; Gerron G.G.; Observations on the plasma amino acids of patients with acute leukemia. Cancer Res 1971,31(8),1159-1165","journal-title":"Cancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"40146","DOI":"10.1038\/srep40146","volume":"7","author":"Wang L.","year":"2017","unstructured":"Wang L.; Liu S.; Yang W.; Yu H.; Zhang L.; Ma P.; Wu P.; Li X.; Cho K.; Xue S.; Jiang B.; Plasma amino acid profile in patients with aortic dissection. Sci Rep 2017,7(1),40146","journal-title":"Sci Rep"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10545-013-9592-4","volume":"36","author":"van der Crabben S.N.","year":"2013","unstructured":"van der Crabben S.N.; Verhoeven-Duif N.M.; Brilstra E.H.; Van Maldergem L.; Coskun T.; Rubio-Gozalbo E.; Berger R.; de Koning T.J.; An update on serine deficiency disorders. J Inherit Metab Dis 2013,36(4),613-619","journal-title":"J Inherit Metab Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejmhg.2014.02.002","volume":"15","author":"ElBaz F.M.","year":"2014","unstructured":"ElBaz F.M.; Zaki M.M.; Youssef A.M.; ElDorry G.F.; Elalfy D.Y.; Study of plasma amino acid levels in children with autism: An Egyptian sample. Egypt J Med Hum Genet 2014,15(2),181-186","journal-title":"Egypt J Med Hum Genet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10803-011-1314-x","volume":"42","author":"Tirouvanziam R.","year":"2012","unstructured":"Tirouvanziam R.; Obukhanych T.V.; Laval J.; Aronov P.A.; Libove R.; Banerjee A.G.; Parker K.J.; O\u2019Hara R.; Herzenberg L.A.; Herzenberg L.A.; Hardan A.Y.; Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with Autism Spectrum Disorders. J Autism Dev Disord 2012,42(5),827-836","journal-title":"J Autism Dev Disord"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0002-8703(68)90168-3","volume":"76","author":"Opie L.H.","year":"1968","unstructured":"Opie L.H.; Metabolism of the heart in health and disease. I. Am Heart J 1968,76(5),685-698","journal-title":"Am Heart J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.lungcan.2015.10.006","volume":"90","author":"Kim H.J.","year":"2015","unstructured":"Kim H.J.; Jang S.H.; Ryu J-S.; Lee J.E.; Kim Y.C.; Lee M.K.; Jang T.W.; Lee S-Y.; Nakamura H.; Nishikata N.; Mori M.; Noguchi Y.; Miyano H.; Lee K.Y.; The performance of a novel amino acid multivariate index for detecting lung cancer: A case control study in Korea. Lung Cancer 2015,90(3),522-527","journal-title":"Lung Cancer"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12893-018-0344-0","volume":"18","author":"Katayama K.","year":"2018","unstructured":"Katayama K.; Higuchi A.; Yamamoto H.; Ikeda A.; Kikuchi S.; Shiozawa M.; Perioperative dynamics and significance of plasma-free amino acid profiles in colorectal cancer. BMC Surg 2018,18(1),11","journal-title":"BMC Surg"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/188731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188731\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/188731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:43:26Z","timestamp":1647107006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188731\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207323666201204143206","relation":{},"ISSN":["1386-2073"],"issn-type":[{"type":"print","value":"1386-2073"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}